Pfiz­er and Bio­haven bring rimegepant to Eu­rope as mi­graine war with Ab­b­Vie heats up

Ab­b­Vie’s been crank­ing up the heat on Bio­haven’s oral mi­graine med Nurtec with its ri­val Qulip­ta. Bio­haven’s so­lu­tion? Take the com­pe­ti­tion over­seas.

Nurtec — or rimegepant, as it’s known chem­i­cal­ly — is now the first drug ap­proved in the EU for both acute and pro­phy­lac­tic treat­ment of mi­graines, where it will be mar­ket­ed as Vy­du­ra. That’s good news for Pfiz­er, which inked a $1.2 bil­lion deal with Bio­haven back in No­vem­ber to take the lead on ex-US sales. And ac­cord­ing to the phar­ma gi­ant, a UK ap­proval should come any time now.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER